Hansoh Pharmaceutical Signs Major Cancer Drug Partnership with Roche

China’s Hansoh Pharmaceutical agreed a licensing partnership with Roche valued at more than $15 billion, announced on 19 October. The agreement includes a $400 million upfront payment, a further $110 million payment after the first year and additional milestone payments tied to the development of cancer therapies.